HepaRegeniX: FDA Grants Orphan Drug Status to Darizmetinib
Tuebingen, Germany — August 26, 2026 HepaRegeniX GmbH announced that the U.S. FDA has granted Orphan Drug Designation (ODD)...
CMS
Advertisement
IMUNON Highlights Phase 3 OVATION 3 Trial at R&D Day
Lawrenceville, New Jersey – August 26, 2026 IMUNON announced plans to host its 2026 R&D Day on September 23...
NeoGenomics Gains Medicare Coverage for RaDaR ST Monitoring
Fort Myers, Florida – August 26, 2026 NeoGenomics announced that its RaDaR ST molecular residual disease (MRD) assay has...
Photocure Advances FDA Reclassification of Blue Light Cystoscopy
Oslo, Norway, August 14, 2026 Photocure ASA has welcomed a new proposal from the U.S. Food and Drug Administration...
Aidoc Secures Medicare Payment for AI Body CT Triage
New York, New York, August 13, 2026 Aidoc announced that its CARE™ Body CT Multi-Triage has received eligibility for...
Advertisements
Andor Health’s ThinkAndor Advances AI-Native Connected Care
ORLANDO, Fla., July 30, 2026 Andor Health announced that its AI-native clinical services operating platform, ThinkAndor®, has reached General...
Bristol Myers Squibb NDA for Mezigdomide Accepted by FDA
PRINCETON, New Jersey, July 13, 2026 Bristol Myers Squibb (BMS) has announced that the U.S. Food and Drug Administration...
Agilent Expands Altura HPLC Portfolio for Biotherapeutics
SANTA CLARA, California, USA, July 8, 2026 Agilent Technologies has expanded its Altura High-Performance Liquid Chromatography (HPLC) portfolio with...
Mindbeam Research Unveils AI-Designed Pain Drug Candidates
BOSTON, Massachusetts, USA, July 9, 2026 Mindbeam Research has unveiled a significant advance in AI-driven drug discovery, demonstrating how...
Insilico Medicine and CMS Expand AI Collaboration for CNS Therapies
HONG KONG, China, July 12, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), and...
Advertisement
